This site is intended for health professionals only

Oral antibiotic launched for travellers’ diarrhoea


Norgine has launched an effective antibiotic for treating non-invasive travellers’ diarrhoea (TD) after a licence was granted for prescription in the UK.

Xifaxanta™ is the first oral antibiotic for the treatment of TD, which remains almost entirely inside the gut (<99%).

As such, the potential for resistance is low, despite Xifaxanta’s use in many countries over several years.

In addition, the risk of systemic side effects and/or drug-drug interactions is reduced.

Xifaxanta™ presents prescribers with an opportunity to treat TD efficiently, but without the concerns of inducing systemic bacterial resistance.

Xifaxanta™ has been available in the USA and other European countries since 2004, but can now be prescribed by UK general practitioners and travel clinics to patients travelling to high-risk destinations as a ‘stand by treatment’.

Administration is via a course of tablets to be taken thrice daily for three days.

The following patients in particular could benefit from taking Xifaxanta™:
Р   Those visiting high-risk regions
Р   Those with increased susceptibility to infection (eg immunocompromised)
Р   Those for whom an episode of TD would adversely disrupt their planned activities
Р   Those returning from travel with uncomplicated TD

A clinical trial found no significant difference between the efficacy of Xifaxanta™ and Ciprofloxacin in non-invasive TD.

The median time from taking XifaxantaTM until the last unformed stool was between 32 and 32½ hours.

Clinical ‘wellness’ was achieved significantly faster with Xifaxanta™-containing regimens compared with Loperamide alone.

Xifaxanta™ was generally well tolerated and associated with a low incidence of adverse events, which were generally mild to moderate in severity.

The most commonly reported events were gastrointestinal in nature, such as flatulence and abdominal pain.

Xifaxanta™ has not been associated with clinically significant cross-resistance to other members of the rifamycin class, in particular Rifampicin.

Travellers’ Diarrhoea

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine